495 results about "Cannabidiol" patented technology

The invention provides a hemostatic composition, a preparation method thereof and a hemostatic product. The hemostatic composition is prepared from the following raw material components in parts by mass: 0.01 to 0.5 part of cannabidiol, 10 to 150 parts of tannic acid modified carboxymethyl chitosan and 5 to 250 parts of crosslinked starch. The tannic acid modified carboxymethyl chitosan is prepared from the following raw material components in parts by mass: 45 to 55 parts of carboxymethyl chitosan and 0.5 to 1.5 parts of tannic acid. The cross-linked starch is prepared from the following raw materials in parts by mass: 95 to 105 parts of carboxymethyl enzymolysis starch and 2 to 5 parts of sodium trimetaphosphate. The hemostatic composition has a good hemostatic effect, and when the hemostatic composition is used in hemostatic products, the hemostatic products can have a good hemostatic effect.

The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present technology relates to a method of treating one or more symptoms of Full Methylation (Fmet) Fragile X Syndrome in a subject that includes administering an effective amount of cannabidiol to the subject such that one or more symptoms of Fragile X Syndrome are treated.

The present invention relates to: a sustained-release injectable composition for treating or preventing neurological disorders; and a method for preparing same. The sustained-release injectable composition uses microparticles containing cannabidiol and continuously releases the cannabidiol for at least one month, and thus can be effective in treating or preventing neurological disorders. In addition, the sustained-release injectable composition includes cannabidiol, which is non-toxic and can be used continuously for a long time due to the absence of side effects from long-term use, and thus can exhibit a therapeutic or prophylactic effect on neurological disorder patients for at least one month through a single injection. Therefore, the sustained-release injectable composition can greatly improve the convenience of administration.

The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg / day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which •modities low-threshold or transient neuronal calcium currents, or •reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.

The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.

The present disclosure relates to the use of cannabidiol (CBD) for the treatment of seizures in patients aged about 1-2 years old. In particular the CBD appears particularly effective in reducing seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dun15q.

The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.

The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.

The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q 11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q 11.2 deletion syndrome are treated in the subject.

The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.

The present invention relates to a group of cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof. The cannabinoid derivatives of the invention are analogues of cannabidiol (CBD). CBD is a non-psychoactive cannabinoid which has been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of the cannabinoid derivatives of the invention

This disclosure herein describes the use of cannabidiol (CBD) with tetramethylpyrazine (TMP) to improve the bioavailability and efficacy of CBD. Behavioral studies indicate that the oral administration of CBD with TMP has a strong anxiolytic effect, increases social behavior in stressed rats, and alleviates anhedonia-like symptoms in stressed rats. These effects were significantly greater than observed with CBD alone, most likely due to increased CBD exposure with TMP administration and / or a metabolism effect of the co-administration of CBD and TMP.

The present invention pertains to a liposome comprising cannabidiol (CBD), a phospholipid component and optionally a sterol component, wherein the liposome comprises more than one bilayer, to related mixtures of liposomes, processes for manufacturing,medicalusesandcompositions.

The invention relates to a preparation method of a cannabidiol nano-lipid carrier, in particular to a preparation method of a cannabidiol nano-lipid carrier with a transdermal absorption function. The invention aims to solve the problem that the existing cannabidiol lipid carrier cannot have high water solubility and high transdermal absorption function at the same time, and is poor in stability and easy to irritate skin. The method comprises the following steps: 1, weighing raw materials; 2, preparing an oil phase; 3, preparing a water phase; 4, mixing; 5, performing ultrasonic homogenization; 6, cooling; and 7, removing impurities. The preparation method is used for preparing the cannabidiol nano-lipid carrier with the transdermal absorption function.

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C6 (CBD-C6), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the cannabinoid can be produced by synthetic means and a method for the production of CBD-C6 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C6 in models of disease.

Disclosed herein are compositions and methods for delivering compositions to a subject in need of treatment for epilepsy. The disclosed compositions are orally delivered. Further disclosed are kits comprising the disclosed compositions as part of a method of delivering cannabidiol and CBD-containing compositions to subjects in need of treatment for epilepsy.

A cannabidiol-containing hemostatic composition, comprising, in parts by mass, 0.05 to 2 parts of cannabidiol, 2 to 40 parts of Bletilla striata extract, 5 to 40 parts of Panax notoginseng extract, 5 to 40 parts of Corydalis yanhusuo extract, 20-80 parts of polyvinylpyrrolidone, 1-20 parts of poloxamer, 0.01-5 parts of an antioxidant, 0.05-10 parts of polyethylene glycol and 30-120 parts of absolute ethyl alcohol. The hemostatic composition can be used as a liquid bandage for emergency treatment of the surface of a wound on the skin.

The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q;, Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The invention provides an industrial production method of cannabidiol, which comprises the following steps: 1) dissolving a cannabis sativa extract with a non-polar solvent, and carrying out first extraction with an alcoholic solution with a first concentration to obtain an oil phase 1 and a water phase 1, the cannabidiol content in the cannabis sativa extract being 40-60%; 2) performing secondary extraction on the oil phase 1 by using an alcoholic solution with a second concentration to obtain an oil phase 2 and a water phase 2; 3) carrying out third extraction on the oil phase 2 by using an alcoholic solution with a third concentration to obtain an oil phase 3 and a water phase 3; and 4) combining the water phase 2 and the water phase 3, concentrating, and crystallizing the concentrate, wherein the first concentration is more than the third concentration and the second concentration is less than the third concentration. According to the method provided by the invention, the production equipment is simple, the column chromatography separation is avoided, the production efficiency is greatly improved, and the ideal yield is obtained.

The invention discloses a hyperbranched anion exchange magnetic solid-phase extraction adsorbent as well as a preparation method and application thereof. The adsorbent Fe3O4 (at) poly (GMA / DVB-WAX) is obtained by carrying out hyperbranched anion modification on Fe3O4 (at) poly (GMA / DVB) microspheres through ethylenediamine and 1, 4-butanediol glycidyl ether. Compared with an Oasis MCX adsorbent and an Oasis HLB adsorbent, the adsorbent provided by the invention has better extraction efficiency. Compared with a column type solid-phase extraction method, the magnetic solid-phase extraction method provided by the invention has the advantages that the sample can be directly extracted without being filtered, the pretreatment step is simplified, and the sensitivity of the method is improved. The invention also establishes a magnetic solid phase extraction-ultra-high performance liquid chromatography-mass spectrometry (MSPE-UHPLC-MS / MS) method for determining four cannabinoids, namely tetrahydrocannabinol, cannabidiol, cannabinol and tetrahydrocannabinoic acid, in the sewage, and the method has the advantages of short pretreatment time, simplicity and convenience in operation, sensitivity and accuracy, and can be used for detecting the four cannabinoids, namely the tetrahydrocannabinol, the cannabidiol, the cannabinol and the tetrahydrocannabinoic acid in the sewage. The trace analysis of the four cannabinoids in the sewage can be met, and the method has very high practicability.

The invention relates to the technical field of biology, in particular to a method for preparing a mesenchymal stem cell exosome with a cancer cell inhibiting effect. According to the application, bioactive substances such as various growth factors, cell factors and exosomes which are rich in the stem cell conditioned culture medium are utilized, and the substances jointly act on cancer cells through various mechanisms such as inducing cell apoptosis, blocking a cell cycle and inhibiting tumor angiogenesis, so that a multi-layer anti-cancer effect is formed; especially, the addition of CBD further enriches or optimizes exosomes in the culture medium, the exosomes may carry more molecules with anticancer characteristics under the induction of CBD, the potential inhibition effect on cancer cells is significantly enhanced, and in addition, the stem cell conditioned culture medium as a treatment tool has a significant treatment effect on cancer cells. Especially, cannabidiol with relatively low cost is combined for treatment, a new thought is provided for developing a cancer treatment strategy with reasonable cost, and the method is expected to reduce the overall treatment cost, so that more patients are benefited.

Disclosed herein are compositions and methods for delivering compositions to a subject in need of treatment for epilepsy. The disclosed compositions are orally delivered. Further disclosed are kits comprising the disclosed compositions as part of a method of delivering cannabidiol and CBD-containing compositions to subjects in need of treatment for epilepsy.

In one aspect, the disclosure relates to new cannabidiol (CBD) analogs produced from allylic monoterpene alcohols and substituted resorcinols in the presence of aryl boronic acids, efficient and mild synthetic methods of making the new CBD analogs, and improved methods of making known CBD analogs. In one aspect, the methods produce low amounts of tetrahydrocannabinol (THC)-like compounds, low amounts of abnormal cannabidiol (abn-CBD) analogs, and higher amounts of CBD analogs, greatly simplifying purification. The methods can be tailored further to produce low amounts of CBD analogs and higher amounts abn-CBD analogs. In the disclosed methods, synthesis parameters can be varied in order to selectively produce a desired normal or abnormal regioisomer.

Pharmaceutical composition comprising one or more cannabinoids (e.g., cannabidiol; 15-25 % w / w), one or more cyclodextrins or cyclodextrin derivatives (e.g., α-cyclodextrin (alpha-CD) or hydropropyl-β

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy syndromes who are concurrently taking the antiepileptic drug clobazam. When CBD is used in combination with clobazam caution should be taken. The patient may need to be cautioned and / or monitored for side effects of a drug-drug interaction 5 between the two medications. In particular the patient should be cautioned and / or monitored for the occurrence of pneumonia. In such a situation the dose of either the CBD and / or the clobazam may be required to be reduced.

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, 6-hydroxy cannabidiol (6-0 H CBD), is a metabolite of CBD. The cannabinoid can be produced by synthetic means and a method for the production of 6-0 H CBD is described herein. In addition, disclosed herein are data which demonstrate the efficacy of 6-0 H CBD in a model of disease.